United States Obesity Therapeutics Market Growth Analysis 2025 | Pfizer acquired Metsera and clinched a $10 billion deal

global obesity therapeutics market size reached US$ 9.19 Billion in 2023 with a rise of US$ 11.03 Billion in 2024 and is expected to reach US$ 63.75 Billion by 2033, growing at a CAGR of 21.6% during the forecast period 2025-2033.

DataM Intelligence has released its latest report on the "Obestity Therapeutics Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Novo Nordisk leads the market with its Phase III GLP-1 receptor agonists, CagriSema and Semaglutide 7.2 mg, which effectively regulate appetite and glucose levels. Rhythm Pharmaceuticals advances with Setmelanotide for rare genetic obesity, while Amgen's MariTide and Boehringer Ingelheim's Survodutide show strong potential in weight and glycemic control.

United States: Recent Industry Developments
✅ October 2025: Eli Lilly reported positive Phase III results for its dual GIP/GLP-1 receptor agonist showing significant weight reduction in obese patients.
✅ September 2025: Pfizer expanded clinical trials for oral obesity drugs targeting appetite and metabolism regulation.
✅ August 2025: Novo Nordisk announced new data supporting long-term cardiovascular benefits of semaglutide in obese individuals.

Japan: Recent Industry Developments
✅ October 2025: Takeda Pharmaceuticals initiated R&D programs focused on peptide-based obesity treatments.
✅ September 2025: Daiichi Sankyo partnered with a biotech firm to develop novel small-molecule therapeutics for obesity management.
✅ August 2025: Japan's Ministry of Health approved expanded indications for GLP-1 analogs in treating obesity-related metabolic disorders.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/competitive-landscape-of-the-global-obesity-therapeutics-market?kb

Latest M&A

Pfizer acquired Metsera (November 2025): Pfizer clinched a $10 billion deal for Metsera, a biotech with next-generation oral and injectable incretin and amylin obesity therapies, beating rival bidder Novo Nordisk. The deal brings four clinical-stage programs into Pfizer's pipeline, including candidates with best-in-class efficacy and safety profiles. Deal closing is anticipated in Q4 2025, pending regulatory approval and shareholder vote.​

Key Highlights

North America leads the global obesity therapeutics market with a 48.5% revenue share in 2024.

Asia-Pacific is the fastest-growing region, registering a 7.7% CAGR in 2024.

GLP-1 receptor agonists dominate the drug class segment with a 45.3% share.

The oral route of administration leads with a 41.3% market share in 2024.

Key Player:

Novo Nordisk, Eli Lilly, VIVUS LLC, Currax Pharmaceuticals LLC, GSK plc, Roche Laboratories Inc, AstraZeneca, Rhythm Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, and KVK Tech, Inc

Key Industry Developments:

In September 2025, Pfizer completed the acquisition of Metsera, a clinical-stage biopharmaceutical company focused on developing next-generation therapies for obesity and cardiometabolic disorders. This acquisition enhanced Pfizer's obesity pipeline with advanced oral, injectable, and combination incretin and non-incretin candidates, underscoring both companies' shared commitment to advancing innovative, effective, and safe metabolic health treatments.

In March 2025, AbbVie signed a licensing agreement with Gubra A/S to develop GUB014295, a promising long-acting amylin analog for obesity management. The partnership leverages AbbVie's development capabilities and Gubra's expertise in peptide-based drug discovery to accelerate the creation of breakthrough therapies for metabolic diseases.

Forecast Projection:

The global Obestity Therapeutics market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.

Market Intelligence Research Process:

The Obestity Therapeutics Market Report by DataM Intelligence offers a comprehensive analysis built on a mix of primary and secondary research. It explores key factors driving the industry, including government policies, market trends, competitive landscape, technological advancements, and upcoming innovations. This in-depth study uncovers both growth opportunities and potential challenges, helping businesses navigate market fluctuations and make data-driven decisions for sustainable success.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=obestity-therapeutics-market

Key Segmentations:

GLP-1 agonists lead obesity drugs with 45.3% share 2024

Oral segment leads obesity therapy with 41.3% share 2024

By Drug Class: (GLP-1 Receptor Agonists, Lipase Inhibitors, Melanocortin-4 Receptor Agonists, Appetite Suppressants and Others)

By Route of Administration: (Parenteral, Oral and Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Latest News and Market Developments

Price Reductions and Medicare Coverage: The Trump administration secured major industry deals with Eli Lilly and Novo Nordisk to sharply cut prices on blockbuster obesity drugs (e.g., Wegovy, Zepbound). New pricing (~$149-$245/month) will coincide with Medicare coverage expansion set for mid-2026, making these drugs accessible to millions more Americans.​

US Obesity Rate Impact: Early survey results show GLP-1-based drugs (like semaglutide and tirzepatide) have brought the national obesity rate down to 37% (from almost 40% a year ago).​

Drug Pipeline Expansion: Eli Lilly is moving its experimental oral obesity drug, orforglipron, into late-stage FDA trials, with expected FDA approval as top priority for 2026. Viking Therapeutics highlighted promising phase 2 data on VK2735 (a dual GLP-1/GIP agonist) showing cardiometabolic benefits and reductions in prediabetes with notable weight loss. A new generation of agents, including triple agonists and oral compounds, has shown up to 24% weight loss over 48 weeks in trials-results rivaling bariatric surgery

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/obestity-therapeutics-market

FAQ's

Q1: How large is the Obestity Therapeutics Market?

Ans: The Obestity Therapeutics Market size was valued at US$ 11.03 Billion in 2024 and is projected to grow to US$ 63.75 Billion by 2033.

Q2: How quickly is the Obestity Therapeutics Market expanding?

Ans: The Obestity Therapeutics Market is forecasted to grow at a CAGR of 21.6% between 2025 and 2032, showing Annual growth momentum

Q3: Which regions are dominating the Obestity Therapeutics Market and which are fastest-growing?

Ans: North America dominating the Obestity Therapeutics market.

Q4: Why is Pfizer's $10 billion bid for Metsera making headlines?

Ans: Pfizer's fierce $10B battle with Novo for Metsera marks one of biotech's biggest showdowns, driven by the potential of Metsera's experimental obesity drugs - a slice of a market expected to hit $150 billion by the next decade.

Latest FDA Developments and Reimbursement

FDA Approvals: The FDA approved Zepbound (tirzepatide) for obesity management (2023) and is accelerating reviews of oral formulations of major GLP-1 drugs (e.g., oral semaglutide, orforglipron).​

Updated Guidance: 2025 FDA guidelines for obesity drug approval now recognize obesity as a disease, require new agents to achieve at least a 5% weight loss vs. placebo, and mandate both arms in trials include lifestyle interventions.​

Insurance/Reimbursement: Medicare will begin covering approved obesity drugs for eligible seniors starting mid-2026, with $50 monthly co-pays and negotiated costs for the government (~$245/month for injectables). This is a landmark change likely to prompt wider private insurance coverage as well

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/obestity-therapeutics-market

Key Drugs in Obesity Therapeutics 2025

Wegovy (semaglutide) - Novo Nordisk; leading GLP-1 injectable, oral version launching late 2025.​

Zepbound (tirzepatide) - Eli Lilly; GLP-1/GIP dual agonist, approved and covered by Medicare.​

Orforglipron - Eli Lilly; experimental oral GLP-1, FDA approval likely in 2026.​

VK2735 - Viking Therapeutics; dual GLP-1/GIP agonist, promising phase 2 data.​

MET-097i & MET-233i - Metsera (now Pfizer pipeline); oral/injectable incretin-based therapies, pending FDA review.​

Emerging multi-agonist oral drugs - Undergoing late-stage trials, showing historic levels of weight loss.

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.